David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Diana Cardona-Grau, Igor Sorokin, Gabriel Leinwand, Charles Welliver 
Volume 69, Issue 5, Pages (May 2016)
Volume 53, Issue 3, Pages (March 2008)
European Urology Focus
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand  Bannakij Lojanapiwat, Choosak Pripatnanont,
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer  Miguel.
European Urology Focus
Volume 69, Issue 5, Pages (May 2016)
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
Volume 74, Issue 2, Pages (August 2018)
Volume 17, Issue 2, Pages (February 2016)
Volume 69, Issue 5, Pages (May 2016)
Volume 51, Issue 4, Pages (April 2007)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Advances in the Treatment of Metastatic Prostate Cancer
Volume 68, Issue 1, Pages (July 2015)
Prostate Cancer Epidemic in Sight?
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Volume 68, Issue 4, Pages (October 2015)
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer  Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Volume 54, Issue 5, Pages (November 2008)
Prostate Cancer Management: What Does the Future Hold?
Volume 66, Issue 3, Pages (September 2014)
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Volume 73, Issue 6, Pages (June 2018)
Counselling the Prostate Cancer Patient
Luis Martínez-Piñeiro  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 72, Issue 1, Pages (July 2017)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 50, Issue 5, Pages (November 2006)
Risk Factors for the Development of Bone Metastases in Prostate Cancer
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Volume 74, Issue 3, Pages (September 2018)
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Volume 71, Issue 4, Pages (April 2017)
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Volume 69, Issue 5, Pages (May 2016)
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Volume 17, Issue 2, Pages (February 2016)
Axel Heidenreich  European Urology Supplements 
Reducing antibiotic use in influenza: challenges and rewards
European Urology Oncology
Highlighting Unmet Needs: Real Patients, Difficult Choices
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Treatment Options in Prostate Cancer Once Primary Therapy Fails
European Urology Oncology
Oncoforum Urology: Prostate Cancer 2008 at a Glance
European Lung Cancer Conference (ELCC) 2016 Organisation
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Does PSA Testing Influence the Natural History of Prostate Cancer?
Introduction European Urology Supplements
Presentation transcript:

Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer  David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono  European Urology Focus  Volume 2, Issue 5, Pages 488-498 (December 2016) DOI: 10.1016/j.euf.2016.10.008 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Natural history of the prostate cancer. Disease states as defined by the Prostate Cancer Clinical Trials Working Group 3 criteria. PSA = prostate-specific antigen; nmCRPC = nonmetastatic castration-resitant prostate cancer; mCRPC = metastatic CRPC. Taken from: Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402–18 [9]. Permission requested from the Journal of Clinical Oncology. European Urology Focus 2016 2, 488-498DOI: (10.1016/j.euf.2016.10.008) Copyright © 2016 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.